Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03078075 · ClinicalTrials.gov registry record · Phase 3
Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
A Phase 3 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 403
- Enrollment target
NCT03078075 is a Phase 3 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 403 participants.
The verdict
NCT03078075, a Phase 3 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 403 participants
- Enrollment target
Study Summary
This is a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Participants will be randomly assigned to the active medication combination (AMC) group or matching placebo group and will receive medications over the course of 12 weeks. Follow-ups will occur in weeks 13 and 16.
Interventions
- DRUG Naltrexone: Vivitrol®
- DRUG Placebo (PLB) Injectable
- DRUG Bupropion: Wellbutrin XL®
- DRUG Placebo (PLB) Oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2017-05-05 |
| Est. Completion | 2019-07-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03078075
The ClinicalTrials.gov registry entry for NCT03078075 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 403 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Naltrexone: Vivitrol® is the first listed.
NCT03078075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03078075 about?
NCT03078075 is a clinical study titled "Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder". This is a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Participants will be randomly assigned to the active medication combination (AMC) group or ma...
What is the current status of trial NCT03078075?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 403 participants. The study started on 2017-05-05. Estimated completion is 2019-07-25.
What interventions are being tested in trial NCT03078075?
The interventions under investigation include: Naltrexone: Vivitrol® (DRUG), Placebo (PLB) Injectable (DRUG), Bupropion: Wellbutrin XL® (DRUG), Placebo (PLB) Oral (DRUG).
Who is sponsoring clinical trial NCT03078075?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.